+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
ID06940674

Evaluating Cannabidiol as an Add-On Treatment to Reduce Opioid Use and Craving in Adults with Opioid Use Disorder on Methadone or Buprenorphine

Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-10-01

450

Participants Needed

2

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether cannabidiol CBD, a non-intoxicating compound, can help reduce craving and relapse in people with opioid use disorder OUD who are maintained on opioid agonist therapy such as methadone or buprenorphine. This phase 3 clinical trial builds on earlier studies that showed CBD reduced craving and anxiety in individuals with heroin use disorder and was safe when combined with opioids. The trial aims to evaluate CBD as an additional treatment to lower illicit opioid use and craving in OUD patients. Participants are randomly assigned to one of three groups receiving either 200 mg CBD twice daily, 400 mg CBD twice daily, or matching placebo capsules twice daily for 24 weeks while continuing their opioid maintenance therapy. The study uses oral capsules of CBD or placebo, and the treatment is given under double-blind, triple-masked conditions. Earlier study phases included pharmacokinetic and safety testing of CBD and shorter treatment periods, leading to this extended 24-week evaluation phase. During the study, participants will undergo regular assessments including urine toxicology tests to detect illicit opioid use, craving and anxiety rating scales, plasma drug levels, and questionnaires about opioid craving, anxiety, and other substance use. Monitoring also includes checking adherence to opioid agonist therapy and study retention. The primary outcome is the percentage of participants with negative urine tests for illicit opioids after 24 weeks. Participants are followed throughout the 24-week treatment to assess the effects of CBD on opioid use and craving.

CONDITIONS

Brief Title

Adjunctive Cannabidiol for Recovery From Opioid Study

Research Team

Z

Zoe Spieler

J

Jonathan Hupf

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here